| Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B (NCT01940315) | DynPort Vaccine Company LLC, A GDIT Company | 2017-10-01 |
| Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant (NCT01122784) | DynPort Vaccine Company LLC, A GDIT Company | 2010-07-01 |
| Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B (NCT00764634) | DynPort Vaccine Company LLC, A GDIT Company | 2008-09-01 |
| Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers (NCT00332956) | DynPort Vaccine Company LLC, A GDIT Company | 2006-05-01 |
| Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine (NCT00109304) | DynPort Vaccine Company LLC, A GDIT Company | 2005-07-01 |
| Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V (NCT00097396) | DynPort Vaccine Company LLC, A GDIT Company | 2004-11-01 |
| Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults (NCT00098098) | DynPort Vaccine Company LLC, A GDIT Company | 2004-08-01 |
| A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults (NCT00057525) | DynPort Vaccine Company LLC, A GDIT Company | 2003-04-01 |
| Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax® (NCT00042094) | DynPort Vaccine Company LLC, A GDIT Company | 2002-03-01 |